OrthoPediatrics

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OrthoPediatrics achieves record revenue growth and eyes international expansion

OrthoPediatrics delivered strong financial performance in 2022, achieving profitability and record revenue growth despite challenges. With a focus on new product launches, international expansion, and surgeon training, the company is well-positioned for continued growth and profitability.

OrthoPediatrics reports robust Q1 earnings, eyes international growth opportunities

OrthoPediatrics had a strong Q1 2023, with increased revenue guidance for the full year. The company remains cautiously optimistic due to staffing dynamics. Focus on new product development, acquisitions, and addressing digital needs of children's hospitals highlight growth strategies.

OrthoPediatrics achieves record Q2 performance amidst growth challenges

OrthoPediatrics delivered strong Q2 results with record child assistance and revenue growth, driven by trauma, deformity, and international segments.
While facing challenges like atypical growth patterns and delays in product launches, the company is well-positioned to capitalize on opportunities in enabling technologies and international expansion.
The focus on long-term growth drivers and strategic acquisitions underscores OrthoPediatrics' commitment to sustainable growth and innovation in pediatric orthopedics.
Overall, OrthoPediatrics' performance highlights operational efficiency, market demand, and a clear path for future growth and expansion.

OrthoPediatrics achieves record revenue in Q3 2023, eyes continued growth

OrthoPediatrics reported strong financial performance in Q3 2023, with record revenue and EBITDA, positioning the company for future growth. Despite challenges in certain segments, opportunities in new product launches, international expansion, and surgeon training initiatives offer avenues for continued success. The company's positive outlook and robust pipeline indicate a promising trajectory for OrthoPediatrics.

OrthoPediatrics achieves record revenue and EBITDA, eyes international expansion

OrthoPediatrics delivered strong financial performance in 2023, setting revenue and EBITDA records. The company's strategic focus on sustainable growth, profitability, and diversification positions it well for future success.

OrthoPediatrics reports robust Q1 growth, raises full-year revenue guidance

OrthoPediatrics demonstrated strong performance in Q1 2024 with significant growth in patients helped, revenue, and key business segments. While facing challenges such as an EBITDA loss and increased expenses, the company's focus on growth, new product launches, and financial targets positions it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OrthoPediatrics Corp. (KIDS) CEO David Bailey on Q2 2021 Results - Earnings Call Transcript

Second Quarter 2021 Revenue Increased 96% Year-over-Year with Continued Strong Domestic Growth Second Quarter 2021 Revenue Increased 96% Year-over-Year with Continued Strong Domestic Growth

OrthoPediatrics Corp. Reports Second Quarter 2021 Financial Results

WARSAW, Ind., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), and Mighty Oak Medical, Inc. are pleased to announce the continuation of their navigation partnership, extending its current five-year deal another five years to August 2027. Since August 2017, OrthoPediatrics has been the exclusive distributor of Mighty Oak Medical's FIREFLY Technology in children's hospitals across the United States. This extended agreement will allow the Company to continue that exclusivity through August 2027.

OrthoPediatrics Corp. and Mighty Oak Medical Extend Exclusive Partnership for FIREFLY Technology in Pediatric Orthopedics

WARSAW, Ind., July 29, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued Diamond sponsorship for the 31st Annual Baltimore Limb Deformity Course (“BLDC”). The highly anticipated industry course will return to its live format, after hosting a virtual meeting in 2020 due to the COVID-19 pandemic.

OrthoPediatrics Corp. Maintains its Diamond Sponsorship for 31st Annual Baltimore Limb Deformity Course (“BLDC”)

WARSAW, Ind., July 22, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today that the Company is scheduled to release its second quarter 2021 financial results on Thursday, August 5, 2021, before the market opens.

OrthoPediatrics Corp. to Report Second Quarter 2021 Financial Results on August 5, 2021

WARSAW, Ind., June 10, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the launch of its 6.5mm/7.3mm Slipped Capital Femoral Epiphysis (“SCFE”) Cannulated Screw system. The company previously received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as expanded indications for its next generation Cannulated Screw System.

OrthoPediatrics Corp. Announces Launch of Next Generation Cannulated Screw System

WARSAW, Ind., June 09, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Mark Throdahl, Executive Chairman, are scheduled to participate in the 2021 JMP Securities Life Sciences Conference on Thursday, June 17, 2021.

OrthoPediatrics Corp. to Present at the 2021 JMP Securities Life Sciences Conference

WARSAW, Ind., June 03, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the senior leadership transition, with David Bailey succeeding Mark Throdahl as Chief Executive Officer. Mark Throdahl will remain with the Company as Executive Chairman.

OrthoPediatrics Corp. Completes Senior Leadership Transition with Appointment of David Bailey as Chief Executive Officer

WARSAW, Ind., May 28, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced the launch of its RESPONSE™ Neuromuscular Scoliosis System. This will be the 36th surgical system the Company has launched.

OrthoPediatrics Corp. Launches RESPONSE™ Neuromuscular Scoliosis System

WARSAW, Ind., May 17, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, has continued the Company's support for the 2021 Pediatric Orthopaedic Society of North America (POSNA) annual meeting, held last week in Dallas, Texas. Despite the lingering effects of the COVID-19 pandemic and travel restrictions, more than 400 attendees from across the United States participated in this year's event. OrthoPediatrics retains its designation as a Double Diamond Sponsor, providing ongoing support of a sub-specialty day symposia and awarding scholarships for residents and fellows to attend the meeting.

OrthoPediatrics Corp. Continues Double Diamond Sponsorship for 2021 POSNA Meeting

OrthoPediatrics' (KIDS) CEO Mark Throdahl on Q1 2021 Results - Earnings Call Transcript

OrthoPediatrics (KIDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

OrthoPediatrics (KIDS) Moves 9.1% Higher: Will This Strength Last?

WARSAW, Ind., April 22, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Mark Throdahl, Chief Executive Officer, are scheduled to participate in a fireside chat at the 7th Annual Truist Securities 2021 Life Sciences Summit on Wednesday, May 5, 2021.

OrthoPediatrics Corp. to Participate in the 7th Annual Truist Securities 2021 Life Sciences Summit

Conference Call to Discuss Results on May 6, 2021 at 8:00 a.m. ET Conference Call to Discuss Results on May 6, 2021 at 8:00 a.m. ET

OrthoPediatrics Corp. to Report First Quarter 2021 Financial Results on May 5, 2021

WARSAW, Ind., March 31, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Mark Throdahl, Chief Executive Officer, are scheduled to participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021.

OrthoPediatrics Corp. to Participate in the 20th Annual Needham Virtual Healthcare Conference

The Internal Brace Option™ is a viable alternative for treating progressive moderate scoliosis in adolescents and a game-changing treatment option for medical providers and patients to consider The Internal Brace Option™ is a viable alternative for treating progressive moderate scoliosis in adolescents and a game-changing treatment option for medical providers and patients to consider

OrthoPediatrics Surpasses Milestones of 500 Scoliosis Correction Cases Worldwide and Nine-Years of Clinical Experience with the ApiFix Procedure

OrthoPediatrics Corp. (KIDS) CEO Mark Throdahl on Q4 2020 Results - Earnings Call Transcript

Full year 2020 revenue of $71.1m compared to full year 2019 revenue of $72.6m, reflecting the impact of COVID-19 on elective surgeries

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2020 Financial Results

NEW YORK, March 9, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of OrthoPediatrics Corp. (NASDAQ: KIDS) resulting from allegations that OrthoPediatrics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased OrthoPediatrics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

KIDS INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages OrthoPediatrics Corp. Investors to Inquire About Class Action Investigation - KIDS

WARSAW, Ind., March 04, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today announced that as of March 2021, it estimates over 200,000 children with orthopedic conditions have been treated with OP products.

OrthoPediatrics Corp. Crosses Milestone Treating 200,000 Children with Orthopedic Conditions

WARSAW, Ind., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today announced it was recently named as one of the 2021 Best Places to Work in Indiana. This is the 5th time the Company has been recognized by the annual program created by the Indiana Chamber of Commerce and Best Companies Group.

2021 Best Places to Work in Indiana

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of OrthoPediatrics Corp. (NASDAQ: KIDS) resulting from allegations that OrthoPediatrics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased OrthoPediatrics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee

ROSEN, A LEADING LAW FIRM, Encourages OrthoPediatrics Corp. Investors to Inquire About Class Action Investigation – KIDS

OrthoPediatrics and ApiFix are committed to helping patients with adolescent idiopathic scoliosis and their families make informed decisions about treatment options in partnership with their physiotherapist and pediatric orthopedic specialist OrthoPediatrics and ApiFix are committed to helping patients with adolescent idiopathic scoliosis and their families make informed decisions about treatment options in partnership with their physiotherapist and pediatric orthopedic specialist

OrthoPediatrics Corp. Launches Dedicated ApiFix Website to Support Game-Changing Spinal Deformity Correction System for Treating AIS

NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS).

SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of OrthoPediatrics Corp. (KIDS) and Encourages Investors to Contact the Firm

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of OrthoPediatrics Corporation ("OrthoPediatrics" or the "Company") (NASDAQ: KIDS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether OrthoPediatrics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...

News for OrthoPediatrics Stock (KIDS)